SOTIO validates the safety and efficacy of its products in a full range of clinical trials — the Group has conducted thirteen trials in Europe and the US since 2012. In 2022/23, the newly developed products BOXR1030 (CAR T), SOT102 (ADC), and SOT201 (immunocytokine) will advance to the clinical trial phase. In late 2021, SOTIO entered into a collaboration agreement with the global pharmaceutical company MSD (Merck) with the purpose of jointly conducting an extensive Phase II clinical study to evaluate the safety and efficacy of IL-15 superagonist SOT101 in combination with MSD’s KEYTRUDA® (pembrolizumab).
In November 2021, SOTIO licensed the technology of South Korea’s LegoChem Biosciences for the development of five new antibody-drug conjugate (ADC) programmes. SOTIO will be responsible for the research, preclinical and clinical development, and commercialisation of the products.
In 2021, SOTIO’s division engaged in the research and development of immunotherapy treatments for cancer based on antibody-drug conjugates was spun out from SOTIO a.s., a biotechnology organisation, into a newly formed entity, SOTIO Biotech a.s. The original company, renamed SCTbio a.s., continues to manufacture modern cell therapy products and provide logistics support for clinical trials.